Source:http://linkedlifedata.com/resource/pubmed/id/18524417
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2008-7-1
|
pubmed:abstractText |
Beneficial effects by both interferon-beta and statin treatment in patients with multiple sclerosis (MS) may be linked to interference with the Th1/Th2 cytokine balance. We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1beta, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-alpha and interferon-gamma, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250microg interferon-beta 1b or with interferon-beta plus 40mg atorvastatin. In treatment naïve patients with MS, a trend for lower TNF-alpha serum levels compared to controls was detected (P=0.08). Interferon-beta treatment increased TNF-alpha levels, while a trend for lowering of IL-5 serum levels was found (P=0.07). Addition of atorvastatin raised IL-12p70 serum levels (P<0.05). Mean levels of two Th2 cytokines (IL-4, IL-10) showed a non-significant increase after addition of atorvastatin. We conclude that interferon-beta and atorvastatin exert divergent action on Th1/Th2 serum cytokines levels in MS. Supplemental atorvastatin might promote a Th1-type response by raising IL-12p70. Further studies are required to support a Th2 cytokine shift by atorvastatin in patients with MS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-5,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0197-0186
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
17-21
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18524417-Adolescent,
pubmed-meshheading:18524417-Adult,
pubmed-meshheading:18524417-Cytokines,
pubmed-meshheading:18524417-Data Interpretation, Statistical,
pubmed-meshheading:18524417-Female,
pubmed-meshheading:18524417-Heptanoic Acids,
pubmed-meshheading:18524417-Humans,
pubmed-meshheading:18524417-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:18524417-Interferon Type I,
pubmed-meshheading:18524417-Interleukin-5,
pubmed-meshheading:18524417-Male,
pubmed-meshheading:18524417-Middle Aged,
pubmed-meshheading:18524417-Multiple Sclerosis,
pubmed-meshheading:18524417-Pyrroles,
pubmed-meshheading:18524417-Recombinant Proteins,
pubmed-meshheading:18524417-Th1 Cells,
pubmed-meshheading:18524417-Th2 Cells
|
pubmed:year |
2008
|
pubmed:articleTitle |
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
|
pubmed:affiliation |
Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland. sellner@lrz.tum.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|